摘要
目的根据血浆纤维蛋白原(FIB)水平给予不同剂量降纤酶治疗,探讨降纤酶个体化剂量治疗急性脑梗死(ACI)的疗效。方法60例急性脑梗死(发病72h内)患者随机分为2组,降纤酶组30例,对照组30例。降纤酶治疗组根据治疗前血浆FIB水平>4g/L,2～4g/L,1.3～2g/L分别给予首剂降纤酶15U,10U,5U,给药后每12h监测一次血浆FIB水平,当血浆FIB水平>1.3g/L时再次给予降纤酶5U,维持患者血浆FIB水平在0.7～1.3g/L之间达7d时间,检测治疗前及治疗7d后血浆凝血酶原时间(PT)、血浆活化部分凝血激酶时间(APTT)、血浆纤维蛋白原(Fg)水平,并在治疗14d后进行神经功能缺损程度评分(CSS)和3个月后日常生活活动(ADL)量表评分,评价临床疗效。结果(1)治疗7d降纤酶组血浆PT、APTT延长,Fg下降,与治疗前及对照组比较,差异均有显著性。(2)治疗14d降纤酶组神经功能缺损程度评分改善,与治疗前及对照组比较,差异均有显著性。(3)临床疗效降纤酶组总有效率80%,对照组总有效率50%,两组比较差异有显著性。(4)治疗后3个月日常生活活动量表评分,两组比较差异无显著性,但(独立+轻度依赖)比例降纤酶组为93.3%,对照组为70.0%,两组比较差异有显著性。(5)治疗期间降纤酶组无颅内外出血,随访3个月无死亡病例发生。结论基于血浆纤维蛋白原水平,应用降纤酶治疗急性脑梗死能快速平稳降低患者血浆纤维蛋白原水平,减少神经功能缺损,提高生活质量。个体化降纤酶治疗安全有效。
Objectives To evaluate the therapeutic effect of individualized defibrase therapy according to the level of plasma fibrinogen （FIB） in patients with acute cerebral infarction （ACI）. Methods Sixty patients with ACI （within 72 h after onset） were randomly divided into defibrase group （n=30） and control group （n=30）. The patients in defibrase group received intravenous defibrase infusion at different first doses （15, 10, and 5 U） according to plasma FIB level （〉4 g/L, 2-4 g/L, and 1.3-2 g/L） before treatment. Plasma FIB was measured every 12 h after the first dose of defibrase, and when plasma FIB was over 1.3 g/L, intravenous infusion of 5 U defibrase was given to maintain plasma FIB within the range of 0.70-1.13 g/L over a period of 7 days. The plasma prothrombin time （PT）, activated partial thromboplastin time （APTT） and FIB before and after the 7-day treatment were measured, and the scores of Chinese stroke scale （CSS） after 14 days of treatment and Activity of Daily Living （ADL） after 3 months were recorded. Results After 7 days of treatment, plasma PT and APTT were significantly prolonged lengthened and plasma FIB was lowered in defibrase group. The scores of CSS improved in defibrase group after 14 days of treatment, showing significant difference from those of the control group. The clinical effective rate was 80% in defibrase group, significantly higher than that in the control group （50%）. The scores of ADL after 3 months were similar between the 2 groups, but the percentage of independent living and mild dependency was significantly higher in defibrase group （93.3% vs 70.0%）. No intmcerebral and extracerebral hemorrhage occurred in defibrase group the during treatment, no did death occur after 3 months of treatment. Conclusion Defibrase therapy based on plasma FIB level can rapidly and effectively lower plasma FIB, reduce neurological impairment and improve the quality of life in patients with ACI.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2009年第10期2124-2127,共4页
Journal of Southern Medical University
关键词
降纤酶
急性脑梗死
治疗
个体化
defibrase
acute cerebral infarction
individualized therapy
